ERBB2 and breast cancer: Analysis of the I-SPY2, NBRST, and FLEX trials further confirmed that MammaPrint H2 is associated with chemosensitivity, with pCR rates ranging from 22% to 29% in patients with HR+HER2- early-stage BC.18-21